PORT WASHINGTON, N.Y.--(BUSINESS WIRE)--Pall Corporation (NYSE:PLL) has introduced a 13 mm Acrodisc® MS syringe filter certified for low extractables in high performance liquid chromatography/mass spectrometry (LCMS) applications. The new 13 mm size, which is designed specifically for small sample analysis using LCMS, complements Pall’s current Acrodisc MS syringe filter offering of a 25 mm filter. The 13 mm Acrodisc MS syringe filter improves the accuracy of testing, enhances LCMS performance, and extends the longevity of testing instrumentation.
The low extractable levels of the new 13 mm Acrodisc MS syringe filter minimize interference with the ionization process and reduce the need for retesting. This lowers costs while minimizing downtime due to unexpected contamination. To ensure high performance, product tubes are packaged individually so that filters not in use remain sealed and protected from external contamination.
Constructed with Pall’s new water wettable polytetrafluoroethylene (WWPTFE) membrane in a unique high density polyethylene housing, the Acrodisc MS syringe filter can be used with both organic and aqueous solvents. It offers excellent chemical resistance and good particulate retention with minimal protein adsorption. This protects instrument columns from particulate build-up and reduces the frequency and cost of replacement. It also enables more consistent LCMS testing performance.
“Pall’s 13 mm Acrodisc MS syringe filter is the newest innovation in our comprehensive line of syringe filters and is suitable for samples as small as 25 µL,” said Larry O’Connell, senior vice president, Pall Laboratory Products. “Our new size will continue to improve the accuracy, cost, and reliability of high performance LCMS testing. The applications for this advancement are extensive and growing rapidly as testing technology advances.”
To learn more about the Acrodisc MS syringe filter and other Pall Life Sciences laboratory products, visit www.pall.com/lab.
Pall Life Sciences
Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. The company’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall technologies are also used in clinical institutions and the food and beverage industries.
About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.
Note to Editors: A high-resolution photograph of the 13 mm Acrodisc MS syringe filter is available for download at www.pall.com/news.